BioLuminescent OptoGenetics (BL-OG): A Novel and Versatile Strategy for Neuromodulation

Information

  • Research Project
  • 9492464
  • ApplicationId
    9492464
  • Core Project Number
    U01NS099709
  • Full Project Number
    3U01NS099709-02S3
  • Serial Number
    099709
  • FOA Number
    PA-16-288
  • Sub Project Id
  • Project Start Date
    9/30/2016 - 7 years ago
  • Project End Date
    6/30/2019 - 4 years ago
  • Program Officer Name
    TALLEY, EDMUND M
  • Budget Start Date
    9/1/2017 - 6 years ago
  • Budget End Date
    6/30/2018 - 5 years ago
  • Fiscal Year
    2017
  • Support Year
    02
  • Suffix
    S3
  • Award Notice Date
    7/26/2017 - 6 years ago

BioLuminescent OptoGenetics (BL-OG): A Novel and Versatile Strategy for Neuromodulation

New tools to selectively regulate neurons have revolutionized causal experimentation. Optogenetics provides an array of elements for specific biophysical control, while designer chemogenetic receptors provide a minimally invasive method to control circuits in vivo by peripheral injection. We have developed a strategy for selective regulation of activity in specific cells that integrates opto- and chemo-genetic approaches, and thus allows manipulation of neuronal activity over a range of spatial and temporal scales in the same experimental animal. Light-sensing molecules (opsins) are activated by biologically produced light through luciferases upon peripheral injection of a small molecule, which crosses the blood-brain barrier. Such BioLuminescence-driven OptoGenetics (?BL-OG?) is a minimally invasive method like chemogenetics, but one that leverages the full array of bioluminescent and optogenetic options. Importantly, BL-OG allows conventional fiber optic activation while at the same time providing chemogenetic access to the same sensors. This opens, in principle, the entire optogenetic toolbox for complementation by a chemogenetic dimension. Further, because different forms of luciferases use non-cross reactive luciferins, multiple distinct effects can be independently and conjointly controlled in the same animal. We demonstrated proof of concept for this technology by using fusion proteins that directly link Gaussia luciferase (GLuc) to opsins, creating luminescent opsins (luminopsin, LMO). Here, we describe our next steps to increase the benefit of this technology for the field. We will expand the range of BL-OG options, increase their potency, and systematically quantify BL-OG impact in vitro and in vivo. In Aim I, we will generate new luciferases with increased light emission and luciferase/luciferin pairs with non- overlapping substrates to allow multiplexing. In Aim II, we will develop an extended toolkit of luciferase-opsin combinations and test their efficacy in vitro. In Aim III, we will validate and quantify the efficacy of bioluminescence activation of neural circuits in vivo by and directly compare stimulation of LMOs versus fiber optics versus DREADDs. Reflecting the basic science and clinical importance of BL-OG and the expertise of the investigators, we will use defined networks in neocortex and thalamus targeted with viral vectors expressing activating and silencing LMOs and DREADDs. The overall outcome of our work will be the optimization and validation of a novel, highly flexible tool set for bimodal optogenetic and chemogenetic interrogation of neuronal circuits in living animals. The proposed work will give the neuroscience community new molecules and comparative data to aid in making an informed decision when choosing among the various tools that may meet their specific experimental needs.

IC Name
NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
  • Activity
    U01
  • Administering IC
    NS
  • Application Type
    3
  • Direct Cost Amount
    7827
  • Indirect Cost Amount
    3483
  • Total Cost
    11310
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    853
  • Ed Inst. Type
    SCHOOLS OF MEDICINE
  • Funding ICs
    NINDS:11310\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    ZNS1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    CENTRAL MICHIGAN UNIVERSITY
  • Organization Department
    NONE
  • Organization DUNS
    624134037
  • Organization City
    MOUNT PLEASANT
  • Organization State
    MI
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    488590001
  • Organization District
    UNITED STATES